This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Veikkola, T. Articles by Alitalo, K. Search for Related Content PubMed PubMed Citation Articles by Veikkola, T. Articles by Alitalo, K.

Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors¹

Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, SF-00014 Helsinki, Finland [T. V., M. K., K. A.], and Department of Medical Biochemistry and Microbiology, Biomedical Center, S-75123 Uppsala, Sweden [L. C-W.]

	Introduction

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 
Endothelial cell signal transduction mechanisms involved in angiogenesis have come into focus in cancer research when it was realized that solid tumors are dependent on neovascularization (1) . Unlike normal human endothelial cells, which are quiescent except in the reproductive organs of fertile women, endothelial cells in tumors express several target features associated with their angiogenic activation. On the other hand, unlike the tumor cells, endothelial cells are readily accessible from the blood circulation, and they are not likely to develop resistant variants to cytostatic therapy (see Ref. 2 ). Vascular targeting may involve either the destruction of existing vessels by exploitation of differences between normal and tumor vessels (3, 4, 5, 6) or inhibition of the tumor angiogenesis process per se (7, 8, 9) . In both scenarios, knowledge of the endothelial cell-specific growth factor receptors and their signal transduction and effector mechanisms is essential and will undoubtedly provide additional points of attack to human cancers. Here we discuss recent results on one important family of endothelial growth factor receptors implicated in angiogenesis. Several excellent reviews have appeared on the same topic and related topics (10, 11, 12, 13, 14) .

The VEGF³ family currently includes five members in addition to the prototype VEGF, namely, PlGF, VEGF-B, VEGF-C, VEGF-D, and Orf virus VEGFs (also called VEGF-E; Refs. 15, 16, 17, 18 and Refs. below). The VEGFs mediate angiogenic signals to the vascular endothelium via high-affinity RTKs. To date, three receptors for the VEGFs have been identified. All three are relatively specific for endothelial cells and demonstrate structural and functional similarities to the PDGF receptor family (see Refs. 14 and 19 ). These receptors are currently designated VEGFR-1, VEGFR-2, and VEGFR-3 and were originally named flt (fms-like tyrosine kinase), KDR (kinase insert domain-containing receptor)/flk-1 (fetal liver kinase-1), and FLT4, respectively (11 , 12 , 20, 21, 22, 23) . All have seven immunoglobulin homology domains in their extracellular part and an intracellular tyrosine kinase signaling domain split by a kinase insert (Fig. 1 ). In adults, VEGFR-1 and VEGFR-2 are expressed mainly in the blood vascular endothelium, whereas VEGFR-3 is restricted largely to the lymphatic endothelium.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. The currently known VEGFs and their receptors. VEGFR-1 and VEGFR-2 have seven extracellular immunoglobulin homology domains, but in VEGFR-3, the fifth immunoglobulin domain is cleaved on receptor processing into disulfide-linked subunits. VEGFR-1 and VEGFR-2 mediate angiogenesis, whereas VEGFR-3 is also involved in lymphangiogenesis. NRP-1 binds to specific COOH-terminal sequences present only in certain VEGFs that bind to VEGFR-1 and/or VEGFR-2. vß3 integrin and VE-cadherin have been found in complexes with activated VEGFR-2, and the latter also associates with an activated VEGFR-3 complex. sVEGFR-1, soluble VEGFR-1; VEC, VE-Cadherin.

VEGFR-1 is a M_r 180,000 transmembrane glycoprotein, but its mRNA can also be spliced to produce a shorter soluble protein consisting of only the first six extracellular immunoglobulin homology domains (20 , 27 , 52) . Such a RNA splice variant, originally detected in a HUVEC cDNA library, encodes 31 unique amino acid residues before a stop codon (52) . VEGFR-2 is a M_r 230,000 protein, and no splice variants have been reported for this receptor. In human VEGFR-3, alternative 3' polyadenylation signals result in a 4.5-kb transcript and a more prevalent 5.8-kb transcript (53) . The latter transcript encodes 65 additional amino acid residues and is the major form detected in tissues. After biosynthesis, the glycosylated M_r 195,000 VEGFR-3 is proteolytically cleaved in the fifth immunoglobulin homology domain, but the resulting M_r 120,000 and M_r 75,000 chains remain linked by a disulfide bond (41 , 54) .

Because hypoxia is a major inducer of VEGF expression in tumors, and the VEGFRs are enhanced in tumor endothelia (see Fig. 2 ) hypoxic regulation of the VEGFR genes has been studied by several groups. In vivo, VEGFR-1 and VEGFR-2 appear to be up-regulated by hypoxia (55, 56, 57) . In vitro, VEGFR-1 expression was increased by hypoxia, whereas VEGFR-2 was either down-regulated or not affected (58, 59, 60) . On the other hand, culture medium from hypoxic cells up-regulated VEGFR-2 protein (59) . The latter effect was probably mediated by VEGF in the culture medium because VEGF treatment has been shown to up-regulate VEGFR-2 expression in endothelial cells and in cerebral slice cultures (61 , 62) . The promoter for VEGFR-1 contains sequences matching the HIF-1 consensus binding site, whereas the closely related HIF-2 may stimulate VEGFR-2 promoter activity (60 , 63 , 64) .

View larger version (123K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Immunostaining of VEGFRs in the vascular endothelium of a melanoma metastasis. Adjacent sections were stained with VEGFR-1, VEGFR-2, VEGFR-3, and control antibodies. Arrows point to endothelial cells. Anti-VEGFR-1 and anti-VEGFR-2 were kind gifts from Dr. Herbert Weich.

	VEGFR Signaling

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

VEGFR-1 and VEGFR-2.
Activation of the MAPK pathway in response to VEGF has been observed in many types of endothelial cells (66, 67, 68, 69, 70, 71, 72, 73, 74) . Interestingly, MAPK activation was delayed in VEGFR-2-transfected fibroblasts, and the mitogenic response was weaker than in endothelial cells, suggesting the involvement of cell type-specific signaling mechanism(s) (71) . In postcapillary venular endothelium, VEGF-mediated induction of MAPK was blocked by inhibitors of nitric oxide synthase, suggesting that nitric oxide contributes to MAPK activation (75) . The role of Ras in the VEGFR-MAPK pathway remains to be elucidated. In primary endothelial cells, Ras was not activated in response to VEGF, and MAPK activation was mediated mainly via a PKC-dependent pathway (74) . PKC has also been implicated in VEGF-induced MAPK activation in VEGFR-2-transfected fibroblasts (71) . Seetharam et al. (66) have observed activation of the Ras guanine nucleotide exchange factor Sos in VEGF-stimulated endothelial cells, but phosphorylation of the adapter protein Shc was barely detectable. On the other hand, Shc phosphorylation in response to VEGF stimulation has been detected in porcine aortic endothelial cells overexpressing VEGFR-2 (69) , and Sck, a Shc homologue, has been shown to interact with the VEGFR-2 cytoplasmic domain in the yeast two-hybrid system (76) . Several investigators have reported phosphorylation of the Ras GTPase-activating protein in endothelial cells after VEGF stimulation (65 , 66 , 77) . Ras GTPase-activating protein activation has also been observed in VEGFR-1-transfected fibroblasts and porcine aortic endothelial cells, but these cells showed no clear MAPK activation or proliferation in response to VEGF (65 , 66) . Interestingly, activation of MAPK in bovine brain capillary endothelial cells by VEGF was selectively inhibited by the M_r 16,000 NH₂-terminal fragment of prolactin, an antiangiogenic factor that also inhibited proliferation of these cells (68 , 78) . In addition to MAPK, VEGF has been shown to activate the p38 stress kinase pathway in HUVECs, and this response has been linked to F-actin reorganization and cell migration (72) .

The PLC--PKC pathway has also been implicated in the mitogenic action of VEGF. VEGFR-1 interacts with the PLC- SH2 domain in the yeast two-hybrid assay (79) , and several groups have reported that VEGF induces the phosphorylation and activation of PLC- (66, 67, 68 , 70 , 71 , 73 , 77 , 80) , leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate to diacylglycerols and inositol 1,4,5-trisphosphate. Inositol 1,4,5-trisphosphate is likely to be responsible for the increase in intracellular Ca²⁺ after VEGF stimulation (27) , whereas diacyl-glycerol, in turn, activates certain PKC isoforms expressed in the target cells. VEGF selectively activated the Ca²⁺-sensitive PKC isoforms and ß2 in bovine aortic endothelial cells, and the mitogenic effect of VEGF in these cell was inhibited by a PKC-ß-selective inhibitor (80) .

Xia et al. (80) reported activation of PI3-K in response to VEGF and demonstrated that PI3-K activity is not required for mitogenesis or activation of PKC (74 , 80) . However, PI3-K was shown to activate Akt, a serine kinase involved in antiapoptotic signaling, and to subsequently deliver a survival signal in HUVECs treated with a VEGFR-2-selective VEGF mutant (81) . VEGFR-2 and the PI3-K/Akt pathway may therefore play a role in VEGF-mediated survival of immature vessels (82) . Akt has also been reported to directly activate endothelial nitric oxide synthase, suggesting that Akt may regulate the increased production of nitric oxide in response to VEGF stimulation (83 , 84) .

STATs are latent cytoplasmic transcription factors. STAT activation by the VEGFRs has been studied in transient transfection assays (85) . All three receptors were shown to be strong activators of STAT3 and STAT5, whereas STAT1 was not activated by the VEGFRs. However, the role of this pathway in endothelial cell biology is unknown.

VEGFR-3.
Whereas both VEGFR-3 isoforms bind to and phosphorylate adapter protein Shc, phosphorylation is stronger in cells expressing the long isoform (54 , 86 , 87) . The Shc PTB domain is required for ligand-induced Shc tyrosine phosphorylation by VEGFR-3 (88) , and mutations in Shc phosphorylation sites increased VEGFR-3 transforming activity in the soft agar assay, indicating that Shc has a negative role in VEGFR-3 signaling.

Both VEGFR-3 isoforms bind Grb2 via its SH2 domain in an inducible manner (54 , 87) . Stimulation of VEGFR-3 also activates MAPK, at least in transfected cells (89) . Similarly, both isoforms bind to a glutathione S-transferase-SH2 (PLC-) fusion protein on stimulation (54 , 86) . In contrast, no direct interaction has been observed with PI3-K (86) . In a human erythroleukemia cell line and in KS cells, VEGF-C induced tyrosine phosphorylation of the cytoskeletal protein paxillin by related adhesion focal tyrosine kinase, a recently identified member of the focal adhesion kinase family (90 , 91) .

Although very little is known about the specific signal transduction of VEGFR-3 in the lymphatic endothelium, mutations in VEGFR-3 have recently been linked with hereditary lymphedema, an autosomal dominant disorder of the lymphatic system that leads to disabling swelling of the extremities and, in rare cases, to lymphangiosarcomas (see Fig. 1 ; Ref. 92 ). This indicates that disturbed VEGFR-3 signaling may play key a role in the development of this disease.

VEGFRs Associate with Cell Adhesion Receptors.
According to new data, endothelial cell proliferation and survival in response to VEGF may require the association of VEGFR-2 with cell surface adhesive proteins. Activated VEGFR-2 was found in a complex with integrin _vß₃, an adhesion molecule specifically expressed on angiogenic endothelium (93) . _vß₃ binds to pericellular matrix proteins containing an arginine-glycine-aspartic acid (RGD) peptide motif, such as vitronectin and fibronectin. _vß₃ has been shown to be involved in the regulation of the cell cycle and the survival of endothelial cells (94, 95, 96) . Various antagonists of this integrin, such as antibodies and cyclic binding peptides, as well as cytokines that interfere with _vß₃ activity, are capable of inhibiting tumor angiogenesis (97) . VEGFR-2 tyrosine phosphorylation and VEGF-induced mitogenicity were enhanced when endothelial cells were plated on the _vß₃ ligand vitronectin, demonstrating that this integrin contributes to VEGFR-2 signaling (93) .

VE-cadherin, an endothelium-specific cell-cell adhesion protein, has also been implicated in molecular interactions with the VEGFRs. Deficiency or truncation of VE-cadherin was lethal in mouse embryos due to increased endothelial cell apoptosis (98) . In normal endothelial cells, VEGFR-2 colocalized with VE-cadherin, and VEGF stimulation resulted in the formation of a complex between VE-cadherin, ß-catenin, PI3-K, and VEGFR-2 and subsequent Akt activation. On the other hand, disruption of VE-cadherin function prevented the endothelial cells from responding to survival signals induced by VEGF. Interestingly, VEGFR-3, but not VEGFR-1, also coimmunoprecipitated with VE-cadherin.

Vascular Permeability May Be Transduced via an Unknown VEGFR.
Tumor vessels are leaky in general, and VEGF is one of the most potent inducers of vascular permeability (99) . VEGF-C also has vascular permeability activity, but the response is not transduced via VEGFR-3 (89) . On the other hand, PlGF, which only binds to VEGFR-1 (36 , 37) , is incapable of inducing permeability. These data imply that either VEGFR-2 or some other as yet unidentified receptor mediates the permeability response. When the third variable domain in the VEGF polypeptide was substituted with the analogous region of PlGF, creating a chimeric molecule with significantly reduced binding to VEGFR-2, the mutant still induced vascular permeability with an activity similar to that of wild-type VEGF (100) . Therefore, it may be that vascular permeability is not mediated by any of the known VEGFRs. Interestingly, the c-Src protein seems to be a necessary mediator of the permeability response because adenoviral vectors expressing VEGF do not induce vascular permeability in mice deficient in c-Src (101) .

Importance of the Cellular Background in VEGF Signaling Studies.
Because most VEGFR signal transduction studies have been carried out using endothelial cells that express more than one type of VEGFR, it has not been possible to attribute the results to a particular receptor. Attempts to study signal transduction by individual receptors using transfected cells have been compromised by the lack of a proper cellular background, which may be an important factor in VEGFR signaling, depending on the substrate under study. Use of receptor-specific ligands or mutants of the VEGF family may offer an alternative approach to these questions (89 , 102) . Another variable in the signal transduction studies is introduced by the heterogeneity of endothelial cells and their tendency to lose differentiated properties in culture. Keeping these aspects in mind, the signaling mechanisms discovered thus far are of interest and may offer possible targets for therapeutic intervention (103) . For example, global assessment of endothelial cell gene expression by RNA microarray analysis may help to better define the activated state of the endothelial cells on angiogenesis and drug treatment. However, for candidate drugs, additional validation has to be provided by experiments in transgenic and gene targeted mice.

	The VEGFRs in Vascular Development

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 
The various VEGFRs are first expressed in the mouse embryonic mesoderm between days 7.5–9.5 of development and distinct expression patterns are also found in 17 week human fetuses (104, 105, 106) . Disruption of any of the three VEGFR genes leads to embryonic lethality. In embryos with targeted null mutations of VEGFR-2, differentiation of both endothelial and hematopoietic cells is blocked, and no blood vessels are formed (107) . However, at least in vitro, endothelial/hematopoietic precursor cells can be derived from VEGFR-2-deficient ES cells, demonstrating that VEGFR-2 is not required for the formation of the common hematopoietic/endothelial progenitor cell, the so-called hemangioblast (108 , 109) . Rather, VEGFR-2 signaling seems to be necessary for endothelial commitment because endothelial development is terminated at an early stage in VEGFR-2-negative ES cell cultures (109) . Hematopoietic requirement for VEGFR-2, on the other hand, is conditional and depends on the cell culture conditions (108 , 109) . Although VEGFR-2 is not required for hemangioblast formation, it appears to be essential for the subsequent VEGF-directed hemangioblast migration to appropriate environments in the developing embryo (108, 109, 110) . In the absence of VEGFR-2 signaling, such cells may rapidly disappear, explaining the lack of endothelial and hematoipoietic precursors in VEGFR-2 null embryos.

In human postnatal hematopoietic tissues, VEGFR-2 apparently persists as a specific marker of hematopoietic stem cells, differentiating them from the lineage-committed hematopoietic precursor cells (111) . Endothelial progenitors or angioblasts have also been isolated from peripheral blood and claimed to be incorporated into sites of active angiogenesis (112 , 113) . Apparently, tissue ischemia or systemic VEGF treatment can mobilize such bone marrow-derived mononuclear progenitor cells (114 , 115) .

Mouse embryos homozygous for a targeted mutation of the VEGFR-1 locus develop an excess of endothelial cells in both embryonic and extraembryonic locations, but the endothelial cells fail to organize into normal vascular channels (116) . The increase in endothelial cell numbers is due to an alteration in cell fate determination among mesenchymal cells, leading to increased hemangioblast commitment (117) . However, when only the tyrosine kinase domain of VEGFR-1 was deleted, leaving the ligand binding extracellular part and the transmembrane domain intact, the gene-targeted mice developed normal vessels and survived (118) . One possible explanation for these and other findings is that during embryogenesis, VEGFR-1 acts as a VEGF sink, regulating the amount of free VEGF available for vascular development. In the absence of VEGFR-1, there would be an excess of free VEGF available to its major signal transducing receptor, VEGFR-2. Therefore, coordinated expression of both VEGFR-1 and VEGFR-2 would be essential for controlled early vascular development.

Disruption of VEGFR-3 led to a defective remodeling of the primary vascular plexus and cardiovascular failure after embryonic day 9.5, but differentiation of endothelial cells, formation of primitive vascular networks, and vascular sprouting occurred normally (119) . This phenotype suggests that VEGFR-3 is required for maturation of the primary vascular plexus into a hierarchy of large and small vessels. Therefore, VEGFR-3 seems to have a general blood vascular function during early development and only later becomes restricted mostly to the lymphatic vascular system. Conditional gene targeting is needed to better define the lymphatic functions of VEGFR-3.

Other VEGF-binding proteins, such as NRP-1, also seem to be involved in the regulation of angiogenesis during development. In normal mouse embryos, NRP-1 is expressed in a temporally restricted manner in endothelial cells of capillaries and blood vessels and in limb buds, and expressed more widely in the mesenchyme (43 , 120) . Targeted disruption of the mouse NRP-1 gene caused severe abnormalities in the peripheral nervous system (121) . Interestingly, VEGF has recently been reported to act also as a neurotrophic survival factor and as a mitogenic agent for Schwann cells (122) . Mice overexpressing NRP-1 formed excess capillaries and abnormal blood vessels and died in utero (120) . It is possible that aberrant angiogenesis in NRP-1 transgenic embryos resulted from inappropriate VEGF activity.

	VEGF and VEGFRs in Tumors

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 
Expression of VEGF and its receptors correlates with the degree of vascularization of many experimental and clinical tumors as detected by in situ hybridization and immunohistochemistry (123, 124, 125, 126, 127, 128, 129, 130, 131, 132) , and both have been used as prognostic indicators of an increased metastatic risk (see Ref. 133 ). Although the detailed molecular mechanism of the "angiogenic switch" by which quiescent endothelium becomes activated is unknown, VEGF seems to be the main inducer of tumor angiogenesis. Tumor hypoxia and oncogenes up-regulate VEGF levels in the neoplastic cells, and hypoxia, in combination with the locally increased VEGF concentrations, up-regulates VEGFR-1 and VEGFR-2 on tumor endothelial cells (62 , 127 , 131) . VEGF-negative ES cells or Ras-transformed fibroblasts grow poorly as tumors in syngeneic mice (134 , 135) . Interestingly, ES cells lacking HIF-1 (deficient in hypoxic induction of VEGF) are tumorigenic. The tumors formed by HIF-1-deficient ES cells are poorly vascularized, but they are apparently more resistant to tumor cell apoptosis under hypoxic conditions (136) . A recent report has suggested that in some cases, tumor vessels can also be formed without endothelial cells (137) .

Autocrine VEGF and VEGFR-1 expression has been shown to occur in angiosarcomas (138) . Of the nonendothelial tumors studied, only a few melanomas and leukemia cell lines aberrantly expressed VEGFRs, whereas several tumor cell lines expressed NRP-1 (22 , 139, 140, 141) .⁴ In tumors associated with the VHL disease, VEGF and VEGFRs are constitutively up-regulated in the absence of hypoxia (see Ref. 142 ). Whereas the normal VHL protein functions as a component of a ubiquitin-protein ligase complex that targets selected proteins such as HIF-1 for ubiquitin-mediated proteolysis (143) , the cells containing a defective VHL protein fail to degrade HIF-1, leading to constitutive up-regulation of many hypoxia-regulated genes, including VEGF (144) .

VEGFR-3 is up-regulated in tumor angiogenesis in general, for example, in breast carcinomas (145 , 146) . In addition, VEGFR-3 has been shown to be increased in the endothelium of lymphatic vessels in metastatic lymph nodes and in lymphangiomas, vascular skin tumors, and KS spindle cells (105 , 147 , 148) .

VEGF and VEGFRs in the Development of AIDS-linked KS.
KS, which is the major neoplastic manifestation of HIV-induced AIDS, is an angiogenic tumor composed of endothelial and spindle cells (for a review, see Ref. 149 ). AIDS-linked KS is always accompanied by infection with HHV-8. In KS lesions, HHV-8 is present in endothelial cells and in spindle cells with endothelial characteristics. HHV-8 encodes for a G-protein-coupled receptor that has been shown to induce VEGF expression in transfected cells (150) , and cell lines derived from AIDS-linked KS also express high levels of the VEGFRs (151) . On the other hand, HIV-1 encodes a transcriptional regulator protein, Tat, which also possesses angiogenic properties. Tat has been shown to bind to and activate VEGFR-2 (152 , 153) , to stimulate KS spindle cell growth (154) , and to induce neovascularization in vivo (155 , 156) and in transgenic mice (157) . VEGFR-3 is also increased in KS (148) , and its ligand, VEGF-C, stimulates the proliferation of KS cells in vitro (158) . It thus seems probable that an autocrine VEGF/VEGFR activation loop plays a part in the development of AIDS-linked KS.

Role of VEGF-induced Vessel Permeability in Tumor Angiogenesis.
In contrast to the well-organized normal blood vessels, tumor vessels are characteristically poorly functioning, leaky endothelial channels with incomplete arteriovenous and perivascular differentiation (159) . Tumor blood flow is temporally and spatially heterogenous, and the interstitial pressure in solid tumors is generally much higher than that in normal tissues. Lack of functional lymphatic vessels is another factor leading to interstitial hypertension (159) . The microvascular hyperpermeability in tumors causes plasma proteins to leak into the extravascular space, leading to clotting of extravasated fibrinogen and introduction of a provisional plasma-derived matrix. Matrix formation precedes and accompanies the onset of endothelial cell migration and vessel sprouting (160) . VEGF derived from hypoxic areas of tumors is likely to mediate increased permeability. VEGF therefore contributes to tumor angiogenesis by both direct and indirect mechanisms: on one hand, VEGF stimulates endothelial cell proliferation and migration; on the other, it renders vessels hyperpermeable, leading to formation of a matrix that supports blood vessel growth. Interestingly, new studies have shown that both VEGF-induced permeability and pathological angiogenesis are attenuated in PlGF-deficient mice.⁵

	Angiogenesis Inhibitors and VEGFR Function

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 
Studies in animal models have illustrated the dependence of tumor vascularization and progression on VEGF signaling. A heterodimeric VEGF variant in which the receptor binding sites at one pole of the ligand were mutated while the other pole was left intact was shown to act as an inhibitor of VEGF function.⁶ A four-fold excess of this mutant VEGF, which bound to its receptors but failed to mediate receptor dimerization and subsequent signaling, was sufficient for almost complete inhibition of vascular permeability and tissue factor expression induced by wild-type VEGF. A dominant negative mutant of VEGFR-2 has been expressed from a retroviral construct and was found to prevent glioblastoma vascularization and growth in nude mice (161) . The study was later extended to other types of tumors, and in most cases, tumor growth was inhibited (162) . Antibodies directed against either VEGFR-2 or the VEGFR-2/VEGF complex have also been effective in inhibiting VEGF-mediated signaling and endothelial cell proliferation in vitro (163, 164, 165) . Because the dominant negative VEGFR-2 inhibits angiogenesis in vivo, compounds that block the tyrosine kinase activity of VEGFR-2 should also prevent neovascularization. Indeed, specific VEGFR-2 tyrosine kinase inhibitors have been shown to abolish VEGF-induced mitogenesis of human endothelial cells in vitro and to have an antitumor effect in mice (103) . Several such compounds (see Ref. 166 ) are currently under evaluation in clinical trials for the treatment of human cancers.

Because soluble extracellular domains of the VEGFRs compete with endothelial cell surface receptors for VEGF binding and inhibit VEGF-induced mitogenicity (52 , 167 , 168) , recombinant VEGFRs retaining high ligand binding affinity also provide the potential for inhibition of tumor angiogenesis. Tumor growth in mice has been shown to be suppressed by the soluble VEGFR-1 and VEGFR-2 receptor "bodies" (168, 169, 170) . Adult mice seem to tolerate such therapy well, whereas newborn mice that receive the inhibitor during their first two postnatal weeks fail to thrive and die (171) . In young animals, systemic administration of soluble VEGFR-1 leads to inhibition of growth plate differentiation and growth of long bones, apparently because VEGF-mediated blood vessel invasion is essential for coupling the resorption of cartilage with bone formation (172) . Interestingly, VEGF also supports osteoclast recruitment and bone resorption, and this effect has been shown to be mediated via VEGFR-1 expressed in osteoclasts (173) . Given the role of VEGF in bone development, anti-VEGF therapy could be useful in treating bone-associated pathologies, for example, bone metastases and osteosarcomas.

	Cross-Talk between Different Receptor Families Required for Angiogenesis

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 
Recent reports on the association of activated VEGFR-2 with other cell surface receptors raise questions on the possible roles these coreceptors play during angiogenesis in vivo. Both NRP-1 and integrin _vß₃ have been shown to increase the mitogenic effects of VEGF (43 , 93) . Because NRP-1 binds only to certain VEGFs (39 , 43, 44, 45) , it could function to specifically potentiate the effects of these family members. In addition, NRP-1 may be able to induce biological responses in cells that express NRP-1 but no VEGFRs. VEGFR-2 association with VE-cadherin and _vß₃ may serve to create active signaling complexes by clustering proteins involved in VEGF-mediated survival signaling (81 , 98) . _vß₃ is required for the full activation of VEGFR-2, suggesting that the complex might regulate tyrosine phosphatase activity or ensure correct juxtaposition of the receptor and putative cytoskeletal substrates.

In addition to the VEGF/VEGFR system, Tie and Eph families of endothelial tyrosine kinases have important functions in the formation and maintenance of the vascular system (174, 175, 176, 177, 178, 179, 180) . Tie-1 and Tie-2 are restricted to the vascular endothelium and certain hematopoietic progenitor cells. Four known ligands, the Angs, bind to Tie-2, whereas there are currently no ligands for Tie-1 (Fig. 3 ; Refs. 181, 182, 183, 184, 185 ). Interestingly, recent findings demonstrate that overexpression of Ang-1 leads to the formation of vessels resistant to vascular leakage induced by VEGF (186) . Plasma leakage contributes not only to tumor angiogenesis but also to a variety of other disease processes (160) , and Ang-1 could perhaps be used therapeutically to reverse such adverse effects of VEGF. The Tie-2 pathway has been reported to be essential for tumor growth and angiogenesis (168 , 187 , 188) . In the study by Siemeister et al. (188) , the VEGFR pathway was not sufficient to compensate for the lack of Tie-2 signaling, suggesting the existence of two independent mechanisms, both of which are required for tumor angiogenesis (188) . Interestingly, the antagonistic Tie-2 ligand Ang-2 has been shown to be up-regulated in the endothelial cells of coopted host vessels of certain tumors, and its increased expression preceded and coincided with apoptotic regression of these vessels (189) . Hypoxia, fibroblast growth factor, and VEGF have been shown to increase Ang-2 mRNA in endothelial cells, suggesting important pathways of signal trans-regulation (see Fig. 3 ; Refs. 190 , 191 ). The intense autocrine expression of Ang-2 by endothelial cells may represent a host defense mechanism against the growing tumor because Ang-2 expression in the absence of VEGF has been implicated in destabilizing the interactions of endothelial cells, pericytes, and the surrounding extracellular matrix, which are necessary for endothelial cell survival (182) .

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Schematic structures of the Tie and Tie-2 receptors. Both receptors contain one complete and one incomplete immunoglobulin domain (circles) plus three epidermal growth factor homology domains (ovals) and fibronectin type III homology domains (yellow), followed by a transmembrane domain and a split tyrosine kinase catalytic domain (blue). The Tie-2 receptor binds four ligands; of these, Ang-3 and Ang-4 may be isogenic in mice and humans, although they behave as an inhibitor and a stimulator of the receptor, respectively. The Tie-2 receptor has been implicated in tumor angiogenesis (166 , 184 , 185) . Thus far, ligand(s) for Tie is unknown, on the other hand, Tie might also interact weakly with the Tie-2-ligand complex (question marks), similar to the mode of action of some epidermal growth factors and receptors.

Of other receptor-ligand families, PDGF-B and PDGF receptor ß have been implicated in the establishment of endothelial cell-pericyte interactions (193 , 194) . Transforming growth factor ß is also an important regulator of vascular structures (195) . Endothelial cell-specific members of the TGF-ß receptor family include endoglin and ALK-1. Lack of endoglin led to poor vascular smooth muscle development, arrested endothelial remodeling, and lethality in mouse embryos, demonstrating that endoglin is essential for developmental angiogenesis (196) . On the other hand, elevated endoglin expression has been correlated with the proliferation of tumor endothelial cells (197) , and expression of ALK-1 coincides with sites of vasculogenesis and angiogenesis in early mouse development (198) . Mutations in endoglin or ALK-1 are the cause of hereditary hemorrhagic telangiectasia (199 , 200) . Endothelial cell-specific members of the transmembrane tyrosyl phosphatase and Notch receptor families have also been described (201 , 202) . The functions of some or many of these may at least partially fail in the poorly organized tumor vessels, which in general do not contain pericytes or well-formed basement membranes. A better understanding of the endothelial signal transduction pathways should lead to the development of additional molecular tools for the prevention of tumor angiogenesis.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Finnish Academy of Sciences, The University of Helsinki, the Finnish and Swedish Cancer Research Foundation, the Ludwig Institute for Cancer Research and the Novo Nordisk Foundation.

² To whom requests for reprints should be addressed, at Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, SF-000014 Helsinki, Finland.

³ The abbreviations used are: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; PlGF, placenta growth factor; RTK, receptor tyrosine kinase; PDGF, platelet-derived growth factor; NRP-1, neuropilin-1; HUVEC, human umbilical vein endothelial cell; HIF, hypoxia-inducible factor; MAPK, mitogen-activated protein kinase; PKC, protein kinase C; PLC, phospholipase C; PI3-K, phosphatidylinositol 3'-kinase; STAT, signal transducer and activator of transcription; KS, Kaposi’s sarcoma; VE-cadherin, vascular endothelial cadherin; ES, embryonic stem; VHL, von Hippel-Lindau; HHV-8, human herpes virus-8/KS herpes virus; Ang, angiopoietin.

⁴ Michael Klagsbrun, personal communication.

⁵ Peter Carmeliet and M. Graziella Persico, personal communication.

⁶ Robert de Waal, personal communication.

Received 4/ 2/99. Accepted 11/15/99.

	REFERENCES

Top Introduction VEGFR Signaling The VEGFRs in Vascular... VEGF and VEGFRs in... Angiogenesis Inhibitors and... Cross-Talk between Different... REFERENCES

 

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.[Medline]
2. Kerbel R. S. A cancer therapy resistant to resistance. Nature (Lond.), 390: 335-336, 1997.[Medline]
3. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur. J. Clin. Invest., 29: 733-736, 1999.[Medline]
4. Thorpe P. E., Burrows F. J. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res. Treat., 36: 237-251, 1995.[Medline]
5. Arap W., Pasqualini R., Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 10: 560-565, 1998.[Medline]
6. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F. J. Evidence for the involvement of endothelial cell integrin _vß₃ in the disruption of the tumor vasculature induced by TNF and IFN-. Nat. Med., 4: 408-414, 1998.[Medline]
7. Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284: 808-812, 1999.[Abstract/Free Full Text]
8. Plate K. H. Control of tumor growth via inhibition of tumor angiogenesis. Adv. Exp. Med. Biol., 451: 57-61, 1998.[Medline]
9. Eliceiri B. P., Cheresh D. A. The role of _v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Investig., 103: 1227-1230, 1999.[Medline]
10. Carmeliet P., Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr. Top. Microbiol. Immunol., 237: 133-158, 1999.[Medline]
11. Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol., 237: 59-83, 1999.[Medline]
12. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.[Abstract/Free Full Text]
13. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int., 56: 794-814, 1999.[Medline]
14. Klagsbrun M., D’Amore P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 7: 259-270, 1996.[Medline]
15. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol., 237: 1-30, 1999.[Medline]
16. Persico, M. G., Vincenti, V., and DiPalma, T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). In: L. Claesson-Welsh (ed.), Vascular Growth Factors and Angiogenesis, pp. 31–40. Berlin: Springer-Verlag, 1999.
17. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem., 273: 31273-31282, 1998.[Abstract/Free Full Text]
18. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H. G., Ziche M., Lanz C., Böttner M., Rziha H-J., Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J., 18: 363-374, 1999.[Medline]
19. Shibuya M. Role of VEGF-FLT receptor system in normal and tumor angiogenesis. Adv. Cancer Res., 67: 281-316, 1995.[Medline]
20. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor type tyrosine kinase gene (flt) closely related to the fms family. Oncogene, 5: 519-524, 1990.[Medline]
21. Terman B. I., Carrion M. E., Kovacs E., Rasmussen B. A., Eddy R. L., Shows T. B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 6: 1677-1683, 1991.[Medline]
22. Aprelikova O., Pajusola K., Partanen J., Armstrong E., Alitalo R., Bailey S. K., McMahon J., Wasmuth J., Huebner K., Alitalo K. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res., 52: 746-748, 1992.[Abstract/Free Full Text]
23. Galland F., Karamysheva A., Mattei M-G., Rosnet O., Marchetto S., Birnbaum D. Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene. Genomics, 13: 475-478, 1992.[Medline]
24. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.[Abstract/Free Full Text]
25. Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 5: 1806-1814, 1991.[Abstract/Free Full Text]
26. Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I., Keshet E., Neufeld G. VEGF145, a secreted vascular endothelial cell isoform, that binds to extracellular matrix. J. Biol. Chem., 272: 7151-7158, 1997.[Abstract/Free Full Text]
27. De Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989-991, 1992.[Abstract/Free Full Text]
28. Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., Armellino D. C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.[Medline]
29. Millauer B., Wizigmann-Voos S., Schnürch H., Martinez R., Moller N-P. H., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72: 835-846, 1993.[Medline]
30. Kendall R. L., Wang G., Thomas K. A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun., 226: 324-328, 1996.[Medline]
31. Wiesmann C., Fuh G., Christinger H. W., Eigenbrot C., Wells J. A., de Vos A. M. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell, 91: 695-704, 1997.[Medline]
32. Muller Y. A., Li B., Christinger H. W., Wells J. A., Cunningham B. C., de Vos A. M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. USA, 94: 7192-7197, 1997.[Abstract/Free Full Text]
33. Davis-Smyth T., Chen H., Park J., Presta L. G., Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J., 15: 4919-4927, 1996.[Medline]
34. Barleon B., Totzke F., Herzog C., Blanke S., Kremmer E., Siemeister G., Marme D., Martiny-Baron G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J. Biol. Chem., 272: 10382-10388, 1997.[Abstract/Free Full Text]
35. Davis-Smyth T., Presta L. G., Ferrara N. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. J. Biol. Chem., 273: 3216-3222, 1998.[Abstract/Free Full Text]
36. Park J. E., Chen H. H., Winer J., Houck K. A., Ferrara N. Placental growth factor. Potentiation of vascular endothelial growth factor bioactivity in vitro and in vivo and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 269: 25646-25654, 1994.[Abstract/Free Full Text]
37. Sawano A., Takahashi T., Yamaguchi S., Aonuma M., Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ., 7: 213-221, 1996.[Abstract]
38. Olofsson B., Korpelainen E., Mandriota S., Pepper M. S., Aase K., Kumar V., Gunji Y., Jeltsch M. M., Shibuya M., Alitalo K., Eriksson U. Vascular endothelial growth factor (VEGF) B binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA, 95: 11709-11714, 1998.[Abstract/Free Full Text]
39. Wise L. M., Veikkola T., Mercer A. A., Savory L. J., Fleming S. B., Caesar C., Vitali A., Makinen T., Alitalo K., Stacker S. The vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. USA, 96: 3071-3076, 1999.[Abstract/Free Full Text]
40. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15: 290-298, 1996.[Medline]
41. Lee J., Gray A., Yuan J., Louth S-M., Avraham H., Wood W. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA, 93: 1988-1992, 1996.[Abstract/Free Full Text]
42. Achen M. G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A. F., Alitalo K., Stacker S. A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998.[Abstract/Free Full Text]
43. Soker S., Takashima S., Miao H. Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 92: 735-745, 1998.[Medline]
44. Migdal M., Huppertz B., Tessler S., Comforti A., Shibuya M., Reich R., Baumann H., Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem., 273: 22272-22278, 1998.[Abstract/Free Full Text]
45. Makinen T., Olofsson B., Karpanen T., Hellman U., Soker S., Klagsbrun M., Eriksson U., Alitalo K. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem., 274: 21217-21222, 1999.[Abstract/Free Full Text]
46. DiSalvo J., Bayne M. L., Conn G., Kwok P. W., Trivedi P. G., Soderman D. D., Palisi P. M., Sullivan K. A., Thomas K. A. Purification and characterization of a naturally occurring vascular endothelial growth factor. Placenta growth factor heterodimer. J. Biol. Chem., 270: 7717-7723, 1995.[Abstract/Free Full Text]
47. Cao Y., Chen H., Zhou L., Chiang M-K., Anand-Apte B., Weatherbee J. A., Wang Y., Fang F., Flanagan J. G., Tsang M. L-S. Heterodimers of placenta growth factor/vascular endothelial growth factor. J. Biol. Chem., 271: 3154-3162, 1996.[Abstract/Free Full Text]
48. Olofsson B., Pajusola K., Kaipainen A., Von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R. F., Alitalo K., Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA, 93: 2576-2581, 1996.[Abstract/Free Full Text]
49. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The bidning of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem., 267: 6093-6098, 1992.[Abstract/Free Full Text]
50. Olofsson B., Pajusola K., von Euler G., Chilov D., Alitalo K., Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J. Biol. Chem., 271: 19310-19317, 1996.[Abstract/Free Full Text]
51. Fairbrother W. J., Champe M. A., Chistinger H. W., Keyt B. A., Starovasnik M. A. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure (Lond.), 6: 637-648, 1998.[Medline]
52. Kendall R. L., Thomas K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA, 90: 10705-10709, 1993.[Abstract/Free Full Text]
53. Pajusola K., Aprelikova O., Armstrong E., Morris S., Alitalo K. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxyterminal tails are produced by alternative processing of primary transcripts. Oncogene, 8: 2931-2937, 1993.[Medline]
54. Pajusola K., Aprelikova O., Pelicci G., Weich H., Claesson-Welsh L., Alitalo K. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene, 9: 3545-3555, 1994.[Medline]
55. Tuder R. M., Flook B. E., Voelkel N. F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Investig., 95: 1798-1807, 1995.
56. Li J., Brown L. F., Hibberd M. G., Grossman J. D., Morgan J. P., Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol., 270: H1803-H1811, 1996.[Abstract/Free Full Text]
57. Marti H. H., Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. USA, 95: 15809-15814, 1998.[Abstract/Free Full Text]
58. Takagi H., King G. L., Ferrara N., Aiello L. P. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Investig. Ophthalmol. Vis. Sci., 37: 1311-1321, 1996.[Abstract/Free Full Text]
59. Brogi E., Schatteman G., Wu T., Kim E. A., Varticovski L., Keyt B., Isner J. M. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Investig., 97: 469-476, 1996.[Medline]
60. Gerber H. P., Conorelli F., Park J., Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem., 272: 23659-23667, 1997.[Abstract/Free Full Text]
61. Shen B. Q., Lee D. Y., Gerber H. P., Keyt B. A., Ferrara N., Zioncheck T. F. Homologous upregulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J. Biol. Chem., 273: 29979-29985, 1998.[Abstract/Free Full Text]
62. Kremer C., Breier G., Risau W., Plate K. H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res., 57: 3852-3859, 1997.[Abstract/Free Full Text]
63. Ikeda T., Wakiya K., Shibuya M. Characterization of the promoter region for the flt-1 tyrosine kinase gene, a receptor for vascular endothelial growth factor. Growth Factors, 13: 151-162, 1996.[Medline]
64. Kappel A., Volker R., Damert A., Flamme I., Risau W., Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood, 93: 4284-4292, 1999.[Abstract/Free Full Text]
65. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269: 26988-26995, 1994.[Abstract/Free Full Text]
66. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene, 10: 135-147, 1995.[Medline]
67. Landgren E., Schiller P., Cao Y., Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C- and migration of endothelial cells expressing Flt 1. Oncogene, 16: 359-367, 1998.[Medline]
68. D’Angelo G., Struman I., Martial J., Weiner R. I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA, 92: 6374-6378, 1995.[Abstract/Free Full Text]
69. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem., 272: 32521-32527, 1997.[Abstract/Free Full Text]
70. Abedi H., Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem., 272: 15442-15451, 1997.[Abstract/Free Full Text]
71. Takahashi T., Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGFR-2) activates the PLC- pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene, 14: 2079-2089, 1997.[Medline]
72. Rousseau S., Houle F., Landry J., Huot J. P38 Map kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene, 15: 2169-2177, 1997.[Medline]
73. Mukhopadhyay D., Nagy J., Manseau E., Dvorak H. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res., 58: 1278-1284, 1998.[Abstract/Free Full Text]
74. Takahashi T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene, 18: 2221-2230, 1999.[Medline]
75. Parenti A., Morbidelli L., Cui X. L., Douglas J. G., Hood J. D., Granger H. J., Ledda F., Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium. J. Biol. Chem., 273: 4220-4226, 1998.[Abstract/Free Full Text]
76. Igarashi K., Shigeta K., Isohara T., Yamano T., Uno I. Sck interacts with KDR and Flt-1 via its SH2 domain. Biochem. Biophys. Res. Commun., 251: 77-82, 1998.[Medline]
77. Guo D., Jia Q., Song H. Y., Warren R. S., Donner D. B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem., 270: 6729-6733, 1995.[Abstract/Free Full Text]
78. Struman I., Bentzien F., Lee H., Mainfroid V., D’Angelo G., Goffin V., Weiner R. I., Martial J. A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA, 96: 1246-1251, 1999.[Abstract/Free Full Text]
79. Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I. Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem. Biophys. Res. Commun., 246: 95-99, 1998.[Medline]
80. Xia P., Aiello L. P., Ishii H., Jiang Z. Y., Park D. J., Robinson G. S., Takagi H., Newsome W. P., Jirousek M. R., King G. L. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Investig., 98: 2018-2026, 1996.[Medline]
81. Gerber H-P., McMurtrey A., Kowalski J., Minhong Y., Keyt B. A., Dixit V., Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. J. Biol. Chem., 273: 30336-30343, 1998.[Abstract/Free Full Text]
82. Alon T., Hemo I., Itin A., Pe’er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med., 1: 1024-1028, 1995.[Medline]
83. Fulton D., Gratton J. P., McCabe T. J., Fontana J., Fujio Y., Walsh K., Franke T. F., Papapetropoulos A., Sessa W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (Lond.), 399: 597-601, 1999.[Medline]
84. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A. M. Activation of nitric oxide sythase in endothelial cells by Akt-dependent phosphorylation. Nature (Lond.), 399: 601-605, 1999.[Medline]
85. Korpelainen E. I., Kärkkäinen M., Gunji Y., Vikkula M., Alitalo K. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene, 18: 1-8, 1999.[Medline]
86. Borg J-P., deLapeyrière O., Noguchi T., Rottapel R., Dubreuil P., Birnbaum D. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene, 10: 973-984, 1995.[Medline]
87. Fournier E., Dubreuil P., Birnbaum D., Borg J-P. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. Oncogene, 11: 921-931, 1995.[Medline]
88. Fournier E., Blaikie P., Rosnet O., Margolis B., Birnbaum D., Borg J-P. Role of tyrosine residues and protein interaction domains of SHC adaptor protein in VEGF receptor 3 signaling. Oncogene, 18: 507-514, 1999.[Medline]
89. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O., Alitalo K. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation and vascular permeability activities. J. Biol. Chem., 273: 6599-6602, 1998.[Abstract/Free Full Text]
90. Liu Z. Y., Ganju R. K., Wang J. F., Ona M. A., Hatch W. C., Zheng T., Avraham S., Gill P., Groopman J. E. Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi’s sarcoma cells. J. Clin. Investig., 99: 1798-1804, 1997.[Medline]
91. Wang J-F., Ganju R., Liu Z-Y., Avraham H., Avraham S., Groopman J. Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor. Blood, 90: 3507-3515, 1997.[Abstract/Free Full Text]
92. Ferrell R. E., Levinson K. L., Esman J. H., Kimak M. A., Lawrence E. C., Barmada M. M., Finegold D. N. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum. Mol. Genet., 7: 2073-2078, 1998.[Abstract/Free Full Text]
93. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of _vß₃ in the activation of vascular endothelial growth factor receptor-2. EMBO J., 18: 882-892, 1999.[Medline]
94. Brooks P. C., Montgomery A. M. P., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin _vß₃ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.[Medline]
95. Strömbland S., Becker J. C., Yebra M., Brooks P. C., Cheresh D. A. Suppression of p53 activity and p21^WAF/CIP1 expression by vascular cell integrin _vß₃ during angiogenesis. J. Clin. Investig., 98: 426-433, 1996.[Medline]
96. Scatena M., Almeida M., Chaisson M. L., Fausto N., Nicosia R. F., Giachelli C. M. NF-B mediates _vß₃ integrin-induced endothelial cell survival. J. Cell Biol., 141: 1083-1093, 1998.[Abstract/Free Full Text]
97. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res., 76: 1-20, 1999.[Medline]
98. Carmeliet P., Lampugnani M-G., Moons L., Breviario F., Compernolle V., Bono F., Balconi G., Spagnuolo R., Oosthuyse B., Dewerchin M., Zanetti A., Angellilo A., Mattot V., Nuyens D., Lutgens E., Clotman F., de Ruiter M. C., Gittenberger-de Groot A., Poelmann R., Lupu F., Herbert J-M., Collen D., Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell, 98: 147-157, 1999.[Medline]
99. Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.[Abstract]
100. Stacker S. A., Vitali A., Caesar C., Domagala T., Groenen L. C., Nice E., Achen M. G., Wilks A. F. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J. Biol. Chem., 274: 34884-34892, 1999.[Abstract/Free Full Text]
101. Eliceiri B. P., Paul R., Schwartzberg P. L., Hood J. D., Leng J., Cheresh D. A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell, 4: 915-924, 1999.[Medline]
102. Keyt B. A., Nguyen H. V., Berleau L. T., Duarte C. M., Park J., Chen H., Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J. Biol. Chem., 271: 5638-5646, 1996.[Abstract/Free Full Text]
103. Fong T. A. T., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K. P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.[Abstract/Free Full Text]
104. Dumont D. J., Fong G-H., Puri M., Gradwohl G., Alitalo K., Breitman M. L. Vascularization of the mouse embryo: a study of flk-1, tek, tie and VEGF expression during development. Mech. Dev., 203: 80-92, 1995.
105. Kaipainen A., Korhonen J., Pajusola K., Aprelikova O., Persico M. G., Terman B. I., Alitalo K. The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J. Exp. Med., 178: 2077-2088, 1993.[Abstract/Free Full Text]
106. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V. M., Fang G-H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc. Natl. Acad. Sci. USA, 92: 3566-3570, 1995.[Abstract/Free Full Text]
107. Shalaby F., Rossant J., Yamaguchi T. P., Gertsenstein M., Wu X. F., Breitman M. L., Schuh A. C. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature (Lond.), 376: 62-66, 1995.[Medline]
108. Schuh A. C., Faloon P., Hu Q-L., Bhimani M., Kyunghee C. In vitro hematopoietic and endothelial potential of flk-1^-/- embryonic stem cells and embryos. Proc. Natl. Acad. Sci. USA, 96: 2159-2164, 1999.[Abstract/Free Full Text]
109. Hidaka M., Stanford W. L., Bernstein A. Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc. Natl. Acad. Sci. USA, 96: 7370-7375, 1999.[Abstract/Free Full Text]
110. Shalaby F., Ho J., Stanford W. L., Fischer K. D., Schuh A. C., Schwartz L., Bernstein A., Rossant J. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell, 89: 981-990, 1997.[Medline]
111. Ziegler B. L., Valtieri M., Porada G. A., Maria R. D., Muller R., Masella B., Gabbianelli M., Casella I., Pelosi E., Bock T., Zanjani E. D., Peschle C. KDR receptor: a key marker defining hematopoietic stem cells. Science (Washington DC), 285: 1553-1558, 1999.[Abstract/Free Full Text]
112. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J. M. Isolation of putative progenitor endothelial cells for angiogenesis. Science (Washington DC), 275: 964-967, 1997.[Abstract/Free Full Text]
113. Shi Q., Rafii S., Wu M. H-D., Wijelath E. S., Yu C., Ishida A., Fujita Y., Kothari S., Mohle R., Sauvage L. R., Moore M. A. S., Storb R. F., Hammond W. P. Evidence for circulationg bone marrow-derived endothelial cells. Blood, 92: 362-367, 1998.[Abstract/Free Full Text]
114. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J. M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 18: 3964-3972, 1999.[Medline]
115. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., Magner M., Isner J. M., Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med., 5: 434-438, 1999.[Medline]
116. Fong G. H., Rossant J., Gertsenstein M., Breitman M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (Lond.), 376: 66-70, 1995.[Medline]
117. Fong G-H., Zhang L., Bryce D-M., Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development (Camb.), 126: 3015-3025, 1999.[Abstract]
118. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA, 4: 9349-9354, 1998.
119. Dumont D., Jussila L., Taipale J., Mustonen T., Pajusola K., Breitman M., Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (Washington DC), 282: 946-949, 1998.[Abstract/Free Full Text]
120. Kitsukawa T., Shimono A., Kawakami A., Kondoh H., Hajime F. Overexpression of a membrane protein, neuropilin, in chimeric mice causes abnormalities in the cardiovascular system, nervous system and limbs. Development (Camb.), 121: 4309-4318, 1995.[Abstract]
121. Kitsukawa T., Shimizu M., Sanbo M., Hirata T., Taniguchi M., Bekku Y., Yagi T., Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron, 19: 995-1005, 1997.[Medline]
122. Sondell M., Lundborg G., Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci., 19: 5731-5740, 1999.[Abstract/Free Full Text]
123. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Dvorak H. F., Senger D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.[Abstract]
124. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.[Abstract/Free Full Text]
125. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Guidi A. J., Dvorak H. F., Senger D. R., Conolly J. L., Schnitt S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.[Medline]
126. Hatva E., Kaipainen A., Mentula P., Jääskeläinen J., Paetau A., Haltia M., Alitalo K. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am. J. Pathol., 146: 368-378, 1995.[Abstract]
127. Plate K. H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.), 359: 845-848, 1992.[Medline]
128. Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55: 3964-3968, 1995.[Abstract/Free Full Text]
129. Warren R. S., Yuan H., Matli M. R., Gillet N. A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig., 95: 1789-1797, 1995.
130. Hatva E., Böhling T., Jääskeläinen J., Persico M. G., Haltia M., Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am. J. Pathol., 148: 763-772, 1996.[Abstract]
131. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.[Medline]
132. Jain R. K., Safabakhsh N., Sckell A., Chen Y., Jiang P., Benjamin L., Yuan F., Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: a role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 95: 10820-10825, 1998.[Abstract/Free Full Text]
133. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol., 147: 9-19, 1995.[Medline]
134. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O’Shea K. S., Powell-Braxton L., Hilan K. J., Moore M. W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond.), 380: 439-442, 1996.[Medline]
135. Grunstein J., Roberts W. G., Mathieu-Costello O., Hanahan D., Johnson R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res., 59: 1592-1598, 1999.[Abstract/Free Full Text]
136. Carmeliet P., Dor Y., Herbert J-M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C. J., Ratcliffe P., Moons L., Jain R. K., Collen D., Keshet E. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond.), 394: 485-490, 1998.[Medline]
137. Maniotis A. J., Folberg R., Hess A., Seftor E., Gardner, L. M. G., Pe’er J., Trent J. M., Meltzer P.S., Hendrix M. J. C. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 155: 739-752, 1999.[Abstract/Free Full Text]
138. Hashimoto M., Ohsawa M., Ohnishi A., Naka N., Hirota S., Kitamura Y., Aozasa K. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab. Invest., 73: 859-863, 1995.[Medline]
139. Cohen T., Gitay-Goren H., Sharon R., Shibuya M., Halaban R., Levi B-Z., Neufeld G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem., 270: 11322-11326, 1995.[Abstract/Free Full Text]
140. Liu B., Earl H. M., Baban D., Shoaibi M., Fabra A., Kerr D. J., Seymor L. W. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem. Biophys. Res. Commun., 217: 721-727, 1995.[Medline]
141. Fiedler W., Graeven U., Süleyman E., Verago S., Kilic N., Stockschläder M., Hossfeld D. K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89: 1870-1875, 1997.[Abstract/Free Full Text]
142. Wizigmann-Voos S., Plate K. H. Pathology, genetics and cell biology of hemangioblastomas. Histol. Histopathol., 11: 1049-1061, 1996.[Medline]
143. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev., 13: 1822-1833, 1999.[Abstract/Free Full Text]
144. Maxwell P. H., Wiesener M. S., Chang G-W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen- dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.[Medline]
145. Valtola R., Salven P., Heikkilä P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., de Waal R., Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol., 154: 1381-1390, 1999.[Abstract/Free Full Text]
146. Partanen T., Alitalo K., Miettinen M. Lack of lymphatic vascular specificity of VEGFR-3: a novel marker for human vascular tumors. Cancer (Phila.), 86: 2406-2412, 1999.[Medline]
147. Lymboussaki A., Partanen T. A., Olofsson B., Thomas-Crusells J., Fletcher C. D. M., de Waal R. M. W., Kaipainen A., Alitalo K. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in cutaneous lymphatic vascular endothelium and in vascular skin lesions. Am. J. Pathol., 153: 395-403, 1998.[Abstract/Free Full Text]
148. Jussila L., Valtola R., Partanen T. A., Salven P., Heikkilä P., Matikainen M-T., Renkonen R., Kaipainen A., Detmar M., Tschachler E., Alitalo R., Alitalo K. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res., 58: 1599-1604, 1998.[Abstract/Free Full Text]
149. Boshoff C., Weiss R. A. Aetiology of Kaposi’s sarcoma: current understanding and implications for therapy. Mol. Med. Today, 3: 488-494, 1997.[Medline]
150. Bais C., Santomasso B., Coso O., Arvanitakis L., Raaka E. G., Gutkind J. S., Asch A. S., Cesarman E., Gerhengorn M. C., Mesri E. A. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (Lond.), 391: 86-89, 1998.[Medline]
151. Masood R., Cai J., Zheng T., Smith D. L., Naidu Y., Gill P. S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. USA, 94: 979-984, 1997.[Abstract/Free Full Text]
152. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., Noonan D., Salio M., Camussi G., Rockl W., Bussolino R. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat. Med., 2: 1371-1375, 1996.[Medline]
153. Ganju R. K., Munshi N., Nair B. C., Liu Z-Y., Gill P., Groopman J. E. Human immunodeficiency virus Tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinase, and components of focal adhesion in Kaposi’s sarcoma cells. J. Virol., 72: 6131-6137, 1998.[Abstract/Free Full Text]
154. Ensoli B., Barillari G., Salahuddin S. Z., Gallo R. C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature (Lond.), 345: 84-86, 1990.[Medline]
155. Albini A., Benelli R., Presta M., Rusnati M., Ziche M., Rubartelli A., Paglialunga G., Bussolino F., Noonan D. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene, 12: 289-297, 1996.[Medline]
156. Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., Cafaro A., Chang H. K., Brady J. N., Gallo R. C. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma. Nature (Lond.), 371: 674-680, 1994.[Medline]
157. Vogel J., Hinrichs S. H., Reynolds R. K., Luciw P. A., Jay G. The HIV tat gene induces dermal lesions resembling Kaposi’s sarcoma in transgenic mice. Nature (Lond.), 335: 606-611, 1988.[Medline]
158. Marchiò S., Primo L., Pagano M., Palestro G., Albini A., Veikkola T., Cascone I., Alitalo K., Bussolino F. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi’s sarcoma cells. J. Biol. Chem., 274: 27617-27622, 1999.[Abstract/Free Full Text]
159. Jain R. J. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med., 4: 655-657, 1998.[Medline]
160. Dvorak H. F., Nagy J. A., Feng D., Brown L. F., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular permeability in angiogenesis. Curr. Top. Microbiol., 237: 97-132, 1999.
161. Millauer B., Shawver L., Plate K., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.[Medline]
162. Millauer B., Longhi M. P., Plate K. H., Shawver L. K., Risau W., Ullrich A., Strawn L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56: 1615-1620, 1996.[Abstract/Free Full Text]
163. Brekken R. A., Huang X., King S. W., Thorpe P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res., 58: 1952-1959, 1998.[Abstract/Free Full Text]
164. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D. J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res., 58: 3209-3214, 1998.[Abstract/Free Full Text]
165. Witte L., Hicklin D. J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., 17: 155-161, 1998.[Medline]
166. Mohammadi M., Froum S., Hamby J. M., Schroeder M. C., Panek R. L., Lu G. H., Eliseenkova A. V., Green D., Schlessinger J., Hubbard S. R. Crystal structure of an angiogenesis inhibitor bound to the VEGF receptor tyrosine kinase domain. EMBO J., 17: 5896-5904, 1998.[Medline]
167. Roeckl W., Hecht D., Sztajer H., Waltenberger J., Yayon A., Weich H. A. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell Res., 241: 161-170, 1998.[Medline]
168. Lin P., Sankar S., Shan S., Dewhirst M. W., Polverini P. J., Quinn T. Q., Peters K. G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ., 9: 49-58, 1998.[Abstract]
169. Goldman C. K., Kendall R. L., Cabrera G., Soroceanu L., Heike Y., Gillespie Y., Siegal G. P., Mao X., Bett A. J., Huckle W. R., Thomas K. A., Curiel D. T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA, 95: 8795-8800, 1998.[Abstract/Free Full Text]
170. Kong H. L., Hecht D., Song W., Kovesdi I., Hackett N. R., Yayon A., Crystal R. G. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther., 9: 823-833, 1998.[Medline]
171. Gerber H-P., Hillan K. J., Ryan A. M., Kowalski J., Keller G-A., Rangell L., Wright B. D., Radtke F., Aguet M., Ferrara N. VEGF is required for growth and survival in neonatal mice. Development (Camb.), 126: 1149-1159, 1999.[Abstract]
172. Gerber H-P., Vu T. H., Ryan A. M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med., 5: 623-628, 1999.[Medline]
173. Niida S., Kaku M., Amano H., Yoshida H., Kataoka H., Nishikawa S., Tanne K., Maeda N., Nishikawa S-I., Kodama H. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteaclastic bone resorption. J. Exp. Med., 190: 293-298, 1999.[Abstract/Free Full Text]
174. Dumont D. J., Gradwohl G., Fong G-H., Puri M. C., Gertsenstein M., Auerbach A., Breitman M. L. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev., 8: 1897-1909, 1994.[Abstract/Free Full Text]
175. Puri M. C., Rossant J., Alitalo K., Bernstein A., Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J., 14: 5884-5891, 1995.[Medline]
176. Sato T. N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (Lond.), 376: 70-74, 1995.[Medline]
177. Partanen, J., and Dumont, D. J. Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. In: L. Claesson-Welsh (ed.), Vascular Growth Factors and Angiogenesis, pp. 159–172. Berlin: Springer-Verlag, 1999.
178. Wang H. U., Chen Z-F., Anderson D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell, 93: 741-753, 1998.[Medline]
179. Adams R. H., Wilkinson G. A., Weiss C., Diella F., Gale N. W., Deutsch U., Risau W., Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev., 13: 295-306, 1999.[Abstract/Free Full Text]
180. Gale N. W., Yancopoulos G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev., 13: 1055-1066, 1999.[Free Full Text]
181. Davis S., Aldrich T. H., Jones P. F., Acheson A., Compton D. L., Jain V., Ryan T. E., Bruno J., Raziejewski C., Maisonpierre P. C., Yancopoulos G. D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87: 1161-1169, 1997.
182. Maisonpierre P. C., Suri C., Jones P. F., Bartunkova S., Wiegand S. J., Radziejewski C., Compton D., McClain J., Aldrich T. H., Papadopoulos N., Daly T. J., Davis S., Sato T. N., Yancopoulos G. D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (Washington DC), 277: 55-60, 1997.[Abstract/Free Full Text]
183. Valenzuela D. M., Griffiths J. A., Rojas J., Aldrich T. H., Jones P. F., Zhou H., McClain J., Copeland N. G., Gilbert D. J., Jenkins N. A., Huang T., Papadopoulous N., Maisonpierre P. C., Davis S., Yancopoulous G. D. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. USA, 96: 1904-1909, 1999.[Abstract/Free Full Text]
184. Nishimura M., Miki T., Yashima R., Yokoi N., Yano H., Sato Y., Seino S. Angiopoietin-3, a novel member of the angiopoietin family. FEBS Lett., 448: 254-256, 1999.[Medline]
185. Kim I., Kwak H. J., Ahn J. E., So J. N., Liu M., Koh K. N., Koh G. Y. Molecular cloning and characterizatin of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett., 443: 353-356, 1999.[Medline]
186. Thurston G., Suri C., Smith K., McClain J., Sato T. N., Yancopoulos G. D., McDonald D. Angiopoietin-1 makes blood vessels resistant to plasma leakage. Science, 286: 2511-2514, 2000.[Abstract/Free Full Text]
187. Peters K. G., Coogan A., Berry D., Marks J., Iglehart J. D., Kontos C. D., Rao P., Sankar S., Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br. J. Cancer, 77: 51-56, 1998.[Medline]
188. Siemeister G., Schirner M., Weindel K., Reusch P., Menrad A., Marme D., Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res., 59: 3185-3191, 1999.[Abstract/Free Full Text]
189. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science (Washington DC), 284: 1994-1998, 1999.[Abstract/Free Full Text]
190. Mandriota S. J., Pepper M. S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res., 83: 852-859, 1998.[Abstract/Free Full Text]
191. Mandriota, S. J., Pyke, C., Di Sanza, C., Quinodoz, P., Pittet, B., and Pepper, M. S. Hypoxia-inducible angiopoietin-2 expression is mimicked by diphenyle iodonium and occurs in the rat brain and skin in response to systemic hypoxia. Am. J. Pathol., in press, 2000.
192. Huynh-Do U., Stein E., Lane A. A., Liu H., Cerretti D. P., Daniel T. O. Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through _vß₃ and ₅ß₁. EMBO J., 18: 2165-2173, 1999.[Medline]
193. Leveen P., Pekny M., Gebre-Medhin S., Swolin B., Larsson E., Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev., 8: 1875-1887, 1994.[Abstract/Free Full Text]
194. Lindahl P., Johansson B. R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Washington DC), 277: 242-245, 1997.[Abstract/Free Full Text]
195. Pepper M. S. Transforming growth factor-ß: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev., 8: 21-43, 1997.[Medline]
196. Li D. Y., Sorensen L. K., Brooke B. S., Urness L. D., Davis E. C., Taylor D. G., Boak B. B., Wendel D. P. Defective angiogenesis in mice lacking endoglin. Science (Washington DC), 284: 1534-1537, 1999.[Abstract/Free Full Text]
197. Miller D. W., Graulich W., Karges B., Stahl S., Ernst M., Ramaswamy A., Sedlacek H. H., Muller R., Adamkiewicz J. Elevated expression of endoglin, a component of the TGF-ß-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer, 81: 568-572, 1999.[Medline]
198. Roelen B. A., van Rooijen M. A., Mummery C. L. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev. Dyn., 209: 418-430, 1997.[Medline]
199. McAllister K. A., Grogg K. M., Johnson D. W., Gallione C. J., Baldwin M. A., Jackson C. E., Helmbold E. A., Markel D. S., McKinnon W. C., Murrell J., McCormick M. K., Pericak-Vance M. A., Heutink P., Oostra B. A., Haitjema T., Westerman C. J. J., Porteous M. E., Guttmacher A. E., Letarte M., Marchuk D. A. Endoglin, a TGF-ß binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 8: 345-351, 1994.[Medline]
200. Berg J. N., Gallione C. J., Stenzel T. T., Johnson D. W., Allen W. P., Schwartz C. E., Jackson C. E., Porteous M. E., Marchuk D. A. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am. J. Hum. Genet., 61: 60-67, 1997.[Medline]
201. Uyttendaele H., Marazzi G., Wu G., Yan Q., Sassoon D., Kitajewski J. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (Camb.), 122: 2251-2259, 1996.[Abstract]
202. Fachinger G., Deutsch U., Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2. Oncogene, 18: 5948-5953, 1999.[Medline]

This article has been cited by other articles:

				J. Baar, P. Silverman, J. Lyons, P. Fu, F. Abdul-Karim, N. Ziats, J. Wasman, P. Hartman, J. Jesberger, L. Dumadag, et al. A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers Clin. Cancer Res., May 15, 2009; 15(10): 3583 - 3590. [Abstract] [Full Text] [PDF]

				N. Baker, S. J. O'Meara, M. Scannell, P. Maderna, and C. Godson Lipoxin A4: Anti-Inflammatory and Anti-Angiogenic Impact on Endothelial Cells J. Immunol., March 15, 2009; 182(6): 3819 - 3826. [Abstract] [Full Text] [PDF]

				J. L. Reverter, J. Nadal, J. M. Fernandez-Novell, J. Ballester, L. Ramio-Lluch, M. M. Rivera, J. Elizalde, S. Abengoechea, J. J. Guinovart, and J. E. Rodriguez-Gil Tyrosine Phosphorylation of Vitreous Inflammatory and Angiogenic Peptides and Proteins in Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1378 - 1382. [Abstract] [Full Text] [PDF]

				S. Tsunoda, H. Sakurai, Y. Saito, Y. Ueno, K. Koizumi, and I. Saiki Massive T-Lymphocyte Infiltration into the Host Stroma Is Essential for Fibroblast Growth Factor-2-Promoted Growth and Metastasis of Mammary Tumors via Neovascular Stability Am. J. Pathol., February 1, 2009; 174(2): 671 - 683. [Abstract] [Full Text] [PDF]

				C. Conrad, H. Niess, R. Huss, S. Huber, I. von Luettichau, P. J. Nelson, H. C. Ott, K.-W. Jauch, and C. J. Bruns Multipotent Mesenchymal Stem Cells Acquire a Lymphendothelial Phenotype and Enhance Lymphatic Regeneration In Vivo Circulation, January 20, 2009; 119(2): 281 - 289. [Abstract] [Full Text] [PDF]

				K. Weinlander, E. Naschberger, M. H. Lehmann, P. Tripal, W. Paster, H. Stockinger, C. Hohenadl, and M. Sturzl Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin {alpha}4 expression FASEB J, December 1, 2008; 22(12): 4168 - 4178. [Abstract] [Full Text] [PDF]

				A. Trindade, S. Ram Kumar, J. S. Scehnet, L. Lopes-da-Costa, J. Becker, W. Jiang, R. Liu, P. S. Gill, and A. Duarte Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos Blood, September 1, 2008; 112(5): 1720 - 1729. [Abstract] [Full Text] [PDF]

				W. Zheng, L. P. Christensen, and R. J. Tomanek Differential effects of cyclic and static stretch on coronary microvascular endothelial cell receptors and vasculogenic/angiogenic responses Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H794 - H800. [Abstract] [Full Text] [PDF]

				D. J. Lee, A. Lyshchik, J. Huamani, D. E. Hallahan, and A. C. Fleischer Relationship Between Retention of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-Targeted Ultrasonographic Contrast Agent and the Level of VEGFR2 Expression in an In Vivo Breast Cancer Model J. Ultrasound Med., June 1, 2008; 27(6): 855 - 866. [Abstract] [Full Text] [PDF]

				P. Mukherjee, A. C. Faber, L. M. Shelton, R. C. Baek, T. C. Chiles, and T. N. Seyfried Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a J. Lipid Res., May 1, 2008; 49(5): 929 - 938. [Abstract] [Full Text] [PDF]

				H. J.M. de Jonge, A. C. Weidenaar, A. ter Elst, H. M. Boezen, F. J.G. Scherpen, J. C.A. Bouma-ter Steege, G. J.L. Kaspers, B. F. Goemans, U. Creutzig, M. Zimmermann, et al. Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia Clin. Cancer Res., February 1, 2008; 14(3): 924 - 930. [Abstract] [Full Text] [PDF]

				S. Fischer, T. Gerriets, C. Wessels, M. Walberer, S. Kostin, E. Stolz, K. Zheleva, A. Hocke, S. Hippenstiel, and K. T. Preissner Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor Blood, October 1, 2007; 110(7): 2457 - 2465. [Abstract] [Full Text] [PDF]

				R. Kumar, V. B. Knick, S. K. Rudolph, J. H. Johnson, R. M. Crosby, M.-C. Crouthamel, T. M. Hopper, C. G. Miller, L. E. Harrington, J. A. Onori, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol. Cancer Ther., July 1, 2007; 6(7): 2012 - 2021. [Abstract] [Full Text] [PDF]

				S. Lee, J. Mandic, and K. J. Van Vliet From the Cover: Chemomechanical mapping of ligand-receptor binding kinetics on cells PNAS, June 5, 2007; 104(23): 9609 - 9614. [Abstract] [Full Text] [PDF]

				T. Chen, M. E. Rose, H. Hwang, R. G. Nines, and G. D. Stoner Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS Carcinogenesis, November 1, 2006; 27(11): 2301 - 2307. [Abstract] [Full Text] [PDF]

				K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res., September 15, 2006; 66(18): 9134 - 9142. [Abstract] [Full Text] [PDF]

				P. Kunz, J. Hoffend, A. Altmann, A. Dimitrakopoulou-Strauss, D. Koczan, M. Eisenhut, G. A. Bonaterra, T. J. Dengler, W. Mier, U. Haberkorn, et al. Angiopoietin-2 Overexpression in Morris Hepatoma Results in Increased Tumor Perfusion and Induction of Critical Angiogenesis-Promoting Genes J. Nucl. Med., September 1, 2006; 47(9): 1515 - 1524. [Abstract] [Full Text] [PDF]

				J. Murtagh, H. Lu, and E. L. Schwartz Taxotere-Induced Inhibition of Human Endothelial Cell Migration Is a Result of Heat Shock Protein 90 Degradation Cancer Res., August 15, 2006; 66(16): 8192 - 8199. [Abstract] [Full Text] [PDF]

				J. Kreuger, I. Nilsson, D. Kerjaschki, T. Petrova, K. Alitalo, and L. Claesson-Welsh Early Lymph Vessel Development From Embryonic Stem Cells Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1073 - 1078. [Abstract] [Full Text] [PDF]

				G. Galabova-Kovacs, D. Matzen, D. Piazzolla, K. Meissl, T. Plyushch, A. P. Chen, A. Silva, and M. Baccarini Essential role of B-Raf in ERK activation during extraembryonic development PNAS, January 31, 2006; 103(5): 1325 - 1330. [Abstract] [Full Text] [PDF]

				S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P. M. Schlag, W. Kemmner, and M. Hocker Vascular Endothelial Growth Factor-D and Its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma J. Clin. Oncol., January 10, 2006; 24(2): 228 - 240. [Abstract] [Full Text] [PDF]

				N. Matsunaga, K. Nakamura, A. Yamamoto, E. Taguchi, H. Tsunoda, and K. Takahashi Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window Mol. Cancer Ther., January 1, 2006; 5(1): 80 - 88. [Abstract] [Full Text] [PDF]

				C. R. Pradeep, E. S. Sunila, and G. Kuttan Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies Integr Cancer Ther, December 1, 2005; 4(4): 315 - 321. [Abstract] [PDF]

				S. Ashikari-Hada, H. Habuchi, Y. Kariya, and K. Kimata Heparin Regulates Vascular Endothelial Growth Factor165-dependent Mitogenic Activity, Tube Formation, and Its Receptor Phosphorylation of Human Endothelial Cells: COMPARISON OF THE EFFECTS OF HEPARIN AND MODIFIED HEPARINS J. Biol. Chem., September 9, 2005; 280(36): 31508 - 31515. [Abstract] [Full Text] [PDF]

				M. V. Backer, T. I. Gaynutdinov, V. Patel, A. K. Bandyopadhyaya, B.T.S. Thirumamagal, W. Tjarks, R. F. Barth, K. Claffey, and J. M. Backer Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature Mol. Cancer Ther., September 1, 2005; 4(9): 1423 - 1429. [Abstract] [Full Text] [PDF]

				L. Ryden, K. Jirstrom, P.-O. Bendahl, M. Ferno, B. Nordenskjold, O. Stal, S. Thorstenson, P.-E. Jonsson, and G. Landberg Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4695 - 4704. [Abstract] [Full Text] [PDF]

				T. Gustafsson, H. Ameln, H. Fischer, C. J. Sundberg, J. A. Timmons, and E. Jansson VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise J Appl Physiol, June 1, 2005; 98(6): 2137 - 2146. [Abstract] [Full Text] [PDF]

				J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold, and W. L. Elliott Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor Mol. Cancer Ther., June 1, 2005; 4(6): 938 - 947. [Abstract] [Full Text] [PDF]

				L. Manenti, E. Riccardi, S. Marchini, E. Naumova, I. Floriani, A. Garofalo, R. Dossi, E. Marrazzo, D. Ribatti, E. Scanziani, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy Mol. Cancer Ther., May 1, 2005; 4(5): 715 - 725. [Abstract] [Full Text] [PDF]

				S.-Y. Chang, H.-J. Ko, T.-H. Heo, and C.-Y. Kang Heparan Sulfate Regulates the Antiangiogenic Activity of Endothelial Monocyte-Activating Polypeptide-II at Acidic pH Mol. Pharmacol., May 1, 2005; 67(5): 1534 - 1543. [Abstract] [Full Text] [PDF]

				Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]

				D. J. Hicklin and L. M. Ellis Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027. [Abstract] [Full Text] [PDF]

				F. Chen, K. Takenaka, E. Ogawa, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka Flt-4-Positive Endothelial Cell Density and Its Clinical Significance in Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8548 - 8553. [Abstract] [Full Text] [PDF]

				V. Mastyugin, E. McWhinnie, M. Labow, and F. Buxton A Quantitative High-Throughput Endothelial Cell Migration Assay J Biomol Screen, December 1, 2004; 9(8): 712 - 718. [Abstract] [PDF]

				K. Nakamura, A. Yamamoto, M. Kamishohara, K. Takahashi, E. Taguchi, T. Miura, K. Kubo, M. Shibuya, and T. Isoe KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth Mol. Cancer Ther., December 1, 2004; 3(12): 1639 - 1649. [Abstract] [Full Text] [PDF]

				E. Bagli, M. Stefaniotou, L. Morbidelli, M. Ziche, K. Psillas, C. Murphy, and T. Fotsis Luteolin Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by Targeting Phosphatidylinositol 3'-Kinase Activity Cancer Res., November 1, 2004; 64(21): 7936 - 7946. [Abstract] [Full Text] [PDF]

				L. Rubbia-Brandt, B. Terris, E. Giostra, B. Dousset, P. Morel, and M. S. Pepper Lymphatic Vessel Density and Vascular Endothelial Growth Factor-C Expression Correlate with Malignant Behavior in Human Pancreatic Endocrine Tumors Clin. Cancer Res., October 15, 2004; 10(20): 6919 - 6928. [Abstract] [Full Text] [PDF]

				B. M. Fenton, S. F. Paoni, and I. Ding Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors Cancer Res., August 15, 2004; 64(16): 5712 - 5719. [Abstract] [Full Text] [PDF]

				Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF]

				R. S. Williams and B. H. Annex Plasticity of Myocytes and Capillaries: A Possible Coordinating Role for VEGF Circ. Res., July 9, 2004; 95(1): 7 - 8. [Full Text] [PDF]

				M. Fukasawa and M. Korc Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines Clin. Cancer Res., May 15, 2004; 10(10): 3327 - 3332. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen, M. W. Lingen, and E. E. Vokes The Expanding Role of Systemic Therapy in Head and Neck Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752. [Abstract] [Full Text] [PDF]

				M. Neid, K. Datta, S. Stephan, I. Khanna, S. Pal, L. Shaw, M. White, and D. Mukhopadhyay Role of Insulin Receptor Substrates and Protein Kinase C-{zeta} in Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Pancreatic Cancer Cells J. Biol. Chem., February 6, 2004; 279(6): 3941 - 3948. [Abstract] [Full Text] [PDF]

				S. Kanda, Y. Miyata, and H. Kanetake Fibroblast Growth Factor-2-mediated Capillary Morphogenesis of Endothelial Cells Requires Signals via Flt-1/Vascular Endothelial Growth Factor Receptor-1: POSSIBLE INVOLVEMENT OF c-Akt J. Biol. Chem., February 6, 2004; 279(6): 4007 - 4016. [Abstract] [Full Text] [PDF]

				Md. R. Abid, S. Guo, T. Minami, K. C. Spokes, K. Ueki, C. Skurk, K. Walsh, and W. C. Aird Vascular Endothelial Growth Factor Activates PI3K/Akt/Forkhead Signaling in Endothelial Cells Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 294 - 300. [Abstract] [Full Text]

				A. L. Goerges and M. A. Nugent pH Regulates Vascular Endothelial Growth Factor Binding to Fibronectin: A MECHANISM FOR CONTROL OF EXTRACELLULAR MATRIX STORAGE AND RELEASE J. Biol. Chem., January 16, 2004; 279(3): 2307 - 2315. [Abstract] [Full Text] [PDF]

				A. N. Witmer, B. C. van Blijswijk, C. J.F. van Noorden, G. F.J.M. Vrensen, and R. O. Schlingemann In Vivo Angiogenic Phenotype of Endothelial Cells and Pericytes Induced by Vascular Endothelial Growth Factor-A J. Histochem. Cytochem., January 1, 2004; 52(1): 39 - 52. [Abstract] [Full Text] [PDF]

				Y. Ren, R. T.-P. Poon, H.-T. Tsui, W.-H. Chen, Z. Li, C. Lau, W.-C. Yu, and S.-T. Fan Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis Clin. Cancer Res., December 1, 2003; 9(16): 5996 - 6001. [Abstract] [Full Text] [PDF]

				Y. Nakamura, H. Yasuoka, M. Tsujimoto, Q. Yang, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, and K. Kakudo Flt-4-Positive Vessel Density Correlates with Vascular Endothelial Growth Factor-D Expression, Nodal Status, and Prognosis in Breast Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5313 - 5317. [Abstract] [Full Text] [PDF]

				B. K. McColl, M. E. Baldwin, S. Roufail, C. Freeman, R. L. Moritz, R. J. Simpson, K. Alitalo, S. A. Stacker, and M. G. Achen Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D J. Exp. Med., September 15, 2003; 198(6): 863 - 868. [Abstract] [Full Text] [PDF]

				F. T. Hall, J. L. Freeman, S. L. Asa, D. G. Jackson, and N. J. Beasley Intratumoral Lymphatics and Lymph Node Metastases in Papillary Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 716 - 719. [Abstract] [Full Text] [PDF]

				A. Luque, D. R. Carpizo, and M. L. Iruela-Arispe ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165 J. Biol. Chem., June 20, 2003; 278(26): 23656 - 23665. [Abstract] [Full Text] [PDF]

				S. Garattini New approaches to cancer therapy Ann. Onc., June 1, 2003; 14(6): 813 - 816. [Full Text] [PDF]

				M. Moser and C. Patterson Thrombin and Vascular Development: A Sticky Subject Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 922 - 930. [Abstract] [Full Text] [PDF]

				A. L. Goerges and M. A. Nugent Regulation of Vascular Endothelial Growth Factor Binding and Activity by Extracellular pH J. Biol. Chem., May 23, 2003; 278(21): 19518 - 19525. [Abstract] [Full Text] [PDF]

				J. Chen, Z. G. Zhang, Y. Li, L. Wang, Y. X. Xu, S. C. Gautam, M. Lu, Z. Zhu, and M. Chopp Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats Circ. Res., April 4, 2003; 92(6): 692 - 699. [Abstract] [Full Text] [PDF]

				L. Yuan, D. Moyon, L. Pardanaud, C. Breant, M. J. Karkkainen, K. Alitalo, and A. Eichmann Abnormal lymphatic vessel development in neuropilin 2 mutant mice Development, March 12, 2003; 129(20): 4797 - 4806. [Abstract] [Full Text] [PDF]

				I. Casella, T. Feccia, C. Chelucci, P. Samoggia, G. Castelli, R. Guerriero, I. Parolini, E. Petrucci, E. Pelosi, O. Morsilli, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor Blood, February 15, 2003; 101(4): 1316 - 1323. [Abstract] [Full Text] [PDF]

				K. Matsumura, M. Hirashima, M. Ogawa, H. Kubo, H. Hisatsune, N. Kondo, S. Nishikawa, T. Chiba, and S.-I. Nishikawa Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3 Blood, February 15, 2003; 101(4): 1367 - 1374. [Abstract] [Full Text] [PDF]

				C. Mallet, O. Feraud, G. Ouengue-Mbele, I. Gaillard, N. Sappay, D. Vittet, and I. Vilgrain Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E156 - E167. [Abstract] [Full Text] [PDF]

				P. Salven, S. Mustjoki, R. Alitalo, K. Alitalo, and S. Rafii VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells Blood, January 1, 2003; 101(1): 168 - 172. [Abstract] [Full Text] [PDF]

				E S Bamberger and C W Perrett Angiogenesis in epithelian ovarian cancer Mol. Pathol., December 1, 2002; 55(6): 348 - 359. [Abstract] [Full Text] [PDF]

				X. Shu, W. Wu, R. D. Mosteller, and D. Broek Sphingosine Kinase Mediates Vascular Endothelial Growth Factor-Induced Activation of Ras and Mitogen-Activated Protein Kinases Mol. Cell. Biol., November 15, 2002; 22(22): 7758 - 7768. [Abstract] [Full Text] [PDF]

				X. Huang, M. K. Wong, H. Yi, S. Watkins, A. D. Laird, S. F. Wolf, and E. Gorelik Combined Therapy of Local and Metastatic 4T1 Breast Tumor in Mice Using SU6668, an Inhibitor of Angiogenic Receptor Tyrosine Kinases, and the Immunostimulator B7.2-IgG Fusion Protein Cancer Res., October 15, 2002; 62(20): 5727 - 5735. [Abstract] [Full Text] [PDF]

				M. Stoner, B. Saville, M. Wormke, D. Dean, R. Burghardt, and S. Safe Hypoxia Induces Proteasome-Dependent Degradation of Estrogen Receptor {alpha} in ZR-75 Breast Cancer Cells Mol. Endocrinol., October 1, 2002; 16(10): 2231 - 2242. [Abstract] [Full Text] [PDF]

				W.-H. Zhu, A. MacIntyre, and R. F. Nicosia Regulation of Angiogenesis by Vascular Endothelial Growth Factor and Angiopoietin-1 in the Rat Aorta Model : Distinct Temporal Patterns of Intracellular Signaling Correlate with Induction of Angiogenic Sprouting Am. J. Pathol., September 1, 2002; 161(3): 823 - 830. [Abstract] [Full Text] [PDF]

				A. SAARISTO, T. VEIKKOLA, B. ENHOLM, M. HYTONEN, J. AROLA, K. PAJUSOLA, P. TURUNEN, M. JELTSCH, M. J. KARKKAINEN, D. KERJASCHKI, et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes FASEB J, July 1, 2002; 16(9): 1041 - 1049. [Abstract] [Full Text] [PDF]

				S.-C. Shih, G. S. Robinson, C. A. Perruzzi, A. Calvo, K. Desai, J. E. Green, I. U. Ali, L. E. H. Smith, and D. R. Senger Molecular Profiling of Angiogenesis Markers Am. J. Pathol., July 1, 2002; 161(1): 35 - 41. [Abstract] [Full Text] [PDF]

				Y. He, K.-i. Kozaki, T. Karpanen, K. Koshikawa, S. Yla-Herttuala, T. Takahashi, and K. Alitalo Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling J Natl Cancer Inst, June 5, 2002; 94(11): 819 - 825. [Abstract] [Full Text] [PDF]

				A. N. Witmer, J. Dai, H. A. Weich, G. F.J.M. Vrensen, and R. O. Schlingemann Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia J. Histochem. Cytochem., June 1, 2002; 50(6): 767 - 778. [Abstract] [Full Text] [PDF]

				M. L. Casanova, F. Larcher, B. Casanova, R. Murillas, M. J. Fernandez-Acenero, C. Villanueva, J. Martinez-Palacio, A. Ullrich, C. J. Conti, and J. L. Jorcano A Critical Role for ras-mediated, Epidermal Growth Factor Receptor-dependent Angiogenesis in Mouse Skin Carcinogenesis Cancer Res., June 1, 2002; 62(12): 3402 - 3407. [Abstract] [Full Text] [PDF]

				O. Salvucci, L. Yao, S. Villalba, A. Sajewicz, S. Pittaluga, and G. Tosato Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1 Blood, April 15, 2002; 99(8): 2703 - 2711. [Abstract] [Full Text] [PDF]

				L. Zhang, D. Yu, D. J. Hicklin, J. A. F. Hannay, L. M. Ellis, and R. E. Pollock Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis Cancer Res., April 1, 2002; 62(7): 2034 - 2042. [Abstract] [Full Text] [PDF]

				Y. Zhou, M. McMaster, K. Woo, M. Janatpour, J. Perry, T. Karpanen, K. Alitalo, C. Damsky, and S. J. Fisher Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome Am. J. Pathol., April 1, 2002; 160(4): 1405 - 1423. [Abstract] [Full Text] [PDF]

				M. A. Hussein Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma Oncologist, April 1, 2002; 7(90001): 20 - 29. [Abstract] [Full Text] [PDF]

				J. D. White, P. W. Hewett, D. Kosuge, T. McCulloch, B. C. Enholm, J. Carmichael, and J. C. Murray Vascular Endothelial Growth Factor-D Expression Is an Independent Prognostic Marker for Survival in Colorectal Carcinoma Cancer Res., March 1, 2002; 62(6): 1669 - 1675. [Abstract] [Full Text] [PDF]

				Y.-Q. Huang, J.-J. Li, L. Hu, M. Lee, and S. Karpatkin Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells Blood, March 1, 2002; 99(5): 1646 - 1650. [Abstract] [Full Text] [PDF]

				J.-C. Tille, J. Wood, S.J. Mandriota, C. Schnell, S. Ferrari, J. Mestan, Z. Zhu, L. Witte, and M. S. Pepper Vascular Endothelial Growth Factor (VEGF) Receptor-2 Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1073 - 1085. [Abstract] [Full Text] [PDF]

				M. E. Baldwin, S. Roufail, M. M. Halford, K. Alitalo, S. A. Stacker, and M. G. Achen Multiple Forms of Mouse Vascular Endothelial Growth Factor-D Are Generated by RNA Splicing and Proteolysis J. Biol. Chem., November 16, 2001; 276(47): 44307 - 44314. [Abstract] [Full Text] [PDF]

				A. F. List Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 24 - 31. [Abstract] [Full Text] [PDF]

				S. Aradhya, H. Woffendin, T. Jakins, T. Bardaro, T. Esposito, A. Smahi, C. Shaw, M. Levy, A. Munnich, M. D'Urso, et al. A recurrent deletion in the ubiquitously expressed NEMO (IKK-{gamma}) gene accounts for the vast majority of incontinentia pigmenti mutations Hum. Mol. Genet., September 1, 2001; 10(19): 2171 - 2179. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]

				R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal Lack of Lymphangiogenesis Despite Coexpression of VEGF-C and Its Receptor Flt-4 in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1422 - 1428. [Abstract] [Full Text]

				C. Jing, C. Beesley, C. S. Foster, H. Chen, P. S. Rudland, D. C. West, H. Fujii, P. H. Smith, and Y. Ke Human Cutaneous Fatty Acid-binding Protein Induces Metastasis by Up-Regulating the Expression of Vascular Endothelial Growth Factor Gene in Rat Rama 37 Model Cells Cancer Res., June 1, 2001; 61(11): 4357 - 4364. [Abstract] [Full Text] [PDF]

				N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1358 - C1366. [Abstract] [Full Text] [PDF]

				K. ILJIN, M. J. KARKKAINEN, E. C. LAWRENCE, M. A. KIMAK, M. UUTELA, J. TAIPALE KATRI PAJUSOLA LEENA ALHONEN, M. HALMEKYTO, D. N. FINEGOLD, R. E. FERRELL, and K. ALITALO VEGFR3 gene structure, regulatory region, and sequence polymorphisms FASEB J, April 1, 2001; 15(6): 1028 - 1036. [Abstract] [Full Text] [PDF]

				A. K. Sood, E. A. Seftor, M. S. Fletcher, L. M. G. Gardner, P. M. Heidger, R. E. Buller, R. E. B. Seftor, and M. J. C. Hendrix Molecular Determinants of Ovarian Cancer Plasticity Am. J. Pathol., April 1, 2001; 158(4): 1279 - 1288. [Abstract] [Full Text] [PDF]

				A. Kadambi, C. Mouta Carreira, C.-o. Yun, T. P. Padera, D. E. J. G. J. Dolmans, P. Carmeliet, D. Fukumura, and R. K. Jain Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A Cancer Res., March 1, 2001; 61(6): 2404 - 2408. [Abstract] [Full Text]

				M. S. Pepper Lymphangiogenesis and Tumor Metastasis: Myth or Reality? Clin. Cancer Res., March 1, 2001; 7(3): 462 - 468. [Abstract] [Full Text]

				E. M. Conway, D. Collen, and P. Carmeliet Molecular mechanisms of blood vessel growth Cardiovasc Res, February 16, 2001; 49(3): 507 - 521. [Full Text] [PDF]

				S. Snitkovsky, T. M. J. Niederman, R. C. Mulligan, and J. A. T. Young Targeting Avian Leukosis Virus Subgroup A Vectors by Using a TVA-VEGF Bridge Protein J. Virol., February 1, 2001; 75(3): 1571 - 1575. [Abstract] [Full Text]

				R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]

				H. Larsson, T. Sjöblom, J. Dixelius, A. Östman, K. Ylinenjärvi, I. Björk, and L. Claesson-Welsh Antiangiogenic Effects of Latent Antithrombin through Perturbed Cell-Matrix Interactions and Apoptosis of Endothelial Cells Cancer Res., December 1, 2000; 60(23): 6723 - 6729. [Abstract] [Full Text]

				S. P. Gunningham, M. J. Currie, C. Han, B. A. Robinson, P. A. E. Scott, A. L. Harris, and S. B. Fox The Short Form of the Alternatively Spliced flt-4 but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers Clin. Cancer Res., November 1, 2000; 6(11): 4278 - 4286. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Veikkola, T. Articles by Alitalo, K. Search for Related Content PubMed PubMed Citation Articles by Veikkola, T. Articles by Alitalo, K.